Abstract:Objective To explore the effects of dialysate calcium concentrations (DCC)on risks of adverse reactions occurred in maintenance hemodialysis patients during dialysis. Methods The subjects were end-stage renal disease (ESRD)patients in stable condition who were treated with maintenance dialysis in the First Affiliated Hospital,Zhejiang University from June to October 2016. According to the DCC,the patients were randomly divided into 3 groups,the 1.25 mmol/L group,the 1.35 mmol/L group,and the 1.50 mmol/L group;the observation time was 12 weeks. The urea clearance index Kt/V,urea reduction rate (URR),mean arterial pressure before and after dialysis,the serum calcium,serum phosphorus,intact parathyroid hormone (iPTH),and alkaline phosphatase (ALP)levels before and after dialysis,and the incidence of muscle spasm,nausea and vomiting,headache,chest tightness,and arrhythmia in hemodialysis patients in the 3 groups were compared. Results A total of 273 patients entered the study,including 159 males and 114 females with ages from 25 to 83 years and average age of (52 ± 9)years. Each of the 1.25 mmol/L,1.35 mmol/L,and 1. 50 mmol/L groups comprised 91 patients. The differences of baseline data in patients in the 3 groups were not statistically significant (P＞0.05). After 12 weeks of hemodialysis,the differences of Kt/V and URR in patients in the 3 groups were not statistically significant (all P＞0.05);the differences of the mean arterial pressures in patients in the 1.25 and 1.35 mmol/L groups [(102 ± 9)and (103 ±11)mmHg,respectively]were not statistically significant (all P ＞0.0.5);the mean arterial pressure in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(120 ± 12) mmHg vs.(103 ± 9)mmHg,P＜0.01]and was higher markedly than that in 1.25 and 1.35 mmol/L groups (all P＜0.01);the serum calcium level in patients in the 1.25 mmol/L group was lower than that before hemodialysis [(1.94 ± 0.31)mmol/L vs.(2.24 ± 0.18)mmol/L,P＜0.01];the serum calcium level in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(2.54 ± 0.18) mmol/L vs.(2.24 ± 0.17)mmol/L,P＜0.01];the iPTH and ALP levels in patients in the 1.25 mmol/L group were higher than those before hemodialysis [(356 ± 68)U vs.(291 ± 49)U,(443 ± 45)U vs. (343 ± 58)U,all P ＜0.01]. During dialysis,the incidence of muscle spasm in patients in the 1.25 mmol/L group was higher than that in the 1.35 mmol/L and 1.50 mmol/L groups [14.28% (13/91)vs. 5.49% (5/91)and 4.39% (4/91),all P ＜0.05];the incidence of headache in patients in the 1.50 mmol/L group was higher than that in the 1.25 mmol/L and 1.35 mmol/L groups [14.28% (13/91)vs. 3.30% (3/91)and 5.49% (5/91),P ＝0.01 and P ＜0.05]. The differences in incidences of chest tightness,arrhythmia,nausea and vomiting were not statistically significant (all P＞0.05). Conclusion The dialysate with calcium concentration of 1.35 mmol/L may reduce the incidence of muscle spasm,does not increase the incidence of hypertension and headache,and effectively reduce the risk of adverse reactions in maintenance hemodialysis patients,while ensuring the adequacy of dialysis.

A Study on Adrenomedullin Level in Patients with Chronic Renal Failure and Its Changes during Dialysis

Pro-adrenomedullin in Acute Decompensation of Liver Cirrhosis: Relationship with Acute-on-chronic Liver Failure and Short-Term Survival.

Cardiac diastolic dysfunction in renal-transplant recipients is associated with increased circulating Adrenomedullin

Changes of Plasma Adrenomedullin and Proadrenomedullin N-terminal 20 Peptide Concentrations in Patients with Heart Failure.

Changes in Adrenomedullin in Patients with Proliferative Diabetic Retinopathy

Elevated Circulating Levels of C-reactive Protein and Adrenomedullin in Patients with Congestive Heart Failure

Bioactive adrenomedullin as a marker of congestion and disease progression in patients with a systemic right ventricle

The Changes of Plasma Urotensin Ⅱ and Adrenomedullin in Patients with Chronic Heart Failure

Primary Research on the Changes of Serum Adiponectin Level and Its Significance in Hemodialysis Patients

Dynamic Changes in Plasma Adrenomedullin Levels and Effect of Enalapril Intervention in Diabetic Rats

Relationship of High-sensitivity C-reactive protein levels and chronic renal failure and dialysis patients

A study of plasma Adiponectin levels and related factors in maintenance hemodialysis and peritoneal dialysis patients

Effect of a Single Hemodialysis on Arterial Function of Patients with End-Stage Renal Disease

The Changes and Clinical Implications of Plasma Urotensin Ⅱ and Adrenomedullin in Patients with Acute Exacerbated Chronic Obstructive Pulmonary Disease Combined with Chronic Heart Failure

The Differences Of Asymmetric Dimethylarginine Removal By Different Dialysis Treatments

Elevation of serum apelin-13 is positively correlated with ADMA in patients on maintenance hemodialysis.

Randomized Controlled Trial of Dialysate Calcium Concentrations on Risks of Adverse Reactions in Hemodialysis Patients During Dialysis

Expression and Role of Adrenomedullin and Its Receptor in Patients with Chronic Obstructive Pulmonary Disease.

Change of heart rate variability and its correlation to intra-dialysis hypotension in end-stage renal disease patients during hemodialysis

Asymmetric dimethylarginine serum concentration in normal weight and obese CKD patients treated with hemodialysis

Adrenomedullin in heart failure: pathophysiology and therapeutic application